Humoral response to cancer as a tool for biomarker discovery
Humoral response to cancer as a tool for biomarker discovery
复制标题
DOI：
10.1016/j.jprot.2009.06.004
复制
发表时间：
2009-08-20
影响因子：
3.3
通讯作者：
Solassol, J.
中科院分区：
文献类型：
--
作者：
Desmetz, C.;Cortijo, C.;Solassol, J.
迫切需要找到对癌症早期诊断和预后具有高敏感性和特异性的相关生物标志物。人类会引发针对癌症的免疫反应，这一点通过在不同类型癌症患者的血清中鉴定出针对多种肿瘤相关抗原的自身抗体而得到部分证明。肿瘤相关抗原及其同源自身抗体的鉴定是发现相关生物标志物的一个有前途的策略。在过去几年中，蛋白质组学方法，包括 SEREX、SERPA 以及最近的蛋白质微阵列，已成为用于鉴定肿瘤相关抗原及其同源自身抗体的主要策略。在这篇综述中，我们的目的是描述这些体液反应研究方法的优点、缺点和最近的改进。 (C) 2009 Elsevier B.V. 保留所有权利。
There is an important need to find relevant biomarkers that show high sensitivity and specificity for early diagnosis and prognosis of cancer. An immune response to cancer is elicited in humans, as demonstrated in part by the identification of autoantibodies against a number of tumor-associated antigens in sera from patients with different types of cancer. Identification of tumor-associated antigens and their cognate autoantibodies is a promising strategy for the discovery of relevant biomarkers. During the past few years, proteomic approaches, including SEREX, SERPA and, more recently, protein microarrays, have been the dominant strategies used to identify tumor-associated antigens and their cognate autoantibodies. in this review, we aim to describe advantages, drawbacks, and recent improvements of these approaches for the study of humoral responses. (C) 2009 Elsevier B.V. All rights reserved.